journal article·2024-08Open access

Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism

Yu Bai, Yanyang Nan, Tao Wu, An Zhu, Xinlei Xie, Yun Sun, Yong Deng, Zihan Dou, Xiaozhi Hu, Rongrui Zhou, Shuwen Xu, Yuanzhen Zhang, Jiajun Fan, Dianwen Ju

Advanced Science· Volume 11· Issue 31

Abstract

Abstract Non‐alcoholic fatty liver disease (NAFLD) is a prominent cause of various chronic metabolic hepatic diseases with limited therapeutics. Rubicon, an essential regulator in lysosomal degradation, is reported to exacerbate hepatic steatosis in NAFLD mice and patients, indicating its probability of being a therapeutic target for NAFLD treatment. In this study, the therapeutic potential of Rubicon blockage is investigated. Lipid nanoparticles carrying Rubicon‐specific CRISPR‐Cas9 components exhibited liver accumulation, cell internalization, and Rubicon knockdown. A single administration of the nanoparticles results in attenuated lipid deposition and hepatic steatosis, with lower circulating lipid levels and decreased adipocyte size in NAFLD mice. Furthermore, the increase of phosphatidylcholine and phosphatidylethanolamine levels can be observed in the NAFLD mice livers after Rubicon silencing, along with regulatory effects on metabolism‐related genes such as CD36, Gpcpd1, Chka, and Lpin2. The results indicate that knockdown of Rubicon improves glycerophospholipid metabolism and thereby ameliorates the NAFLD progression, which provides a potential strategy for NAFLD therapy via the restoration of Rubicon.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Endoplasmic Reticulum Stress and Disease · Pancreatic function and diabetes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics Fudan University School of Pharmacy Shanghai P. R. China

Department of Research and Development Shanghai Proton and Heavy Ion Center Fudan University Cancer Hospital Shanghai 201321 P. R. China

Fudan Zhangjiang Institute Shanghai 201203 P. R. China

Shanghai Hailu Biological Technology Co., Ltd. Shanghai 201200 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Shanghai Rising-Star Program · Shanghai Science and Technology Development Foundation

References (65)

Show source-provided references
1. 10.1053/j.gastro.2020.01.05210.1053/j.gastro.2020.01.052 ↗
2. 10.1002/hep.2852410.1002/hep.28524 ↗
3. 10.1002/hep.2972410.1002/hep.29724 ↗
4. Lee H.‐H. · Gut · 2024 · 73 · 53310.1136/gutjnl-2023-331003 ↗
5. 10.1016/j.jhep.2023.08.02310.1016/j.jhep.2023.08.023 ↗
6. Romero‐Gómez M. · BMJ · 2023 · 38310.1136/bmj-2023-075179 ↗
7. 10.1002/hep.2400110.1002/hep.24001 ↗
8. 10.1093/cvr/cvad09510.1093/cvr/cvad095 ↗
9. 10.1016/j.cell.2021.04.01510.1016/j.cell.2021.04.015 ↗
10. 10.1016/j.molmet.2020.10111510.1016/j.molmet.2020.101115 ↗
11. 10.1038/s41575-021-00502-910.1038/s41575-021-00502-9 ↗
12. 10.1053/j.gastro.2018.06.03110.1053/j.gastro.2018.06.031 ↗
13. 10.1016/j.jhep.2021.11.00910.1016/j.jhep.2021.11.009 ↗
14. 10.1016/j.jhep.2017.10.01510.1016/j.jhep.2017.10.015 ↗
15. 10.1038/ncb184610.1038/ncb1846 ↗
16. 10.4161/auto.909810.4161/auto.9098 ↗
17. 10.1126/sciadv.abo560010.1126/sciadv.abo5600 ↗
18. 10.1038/s41467-020-17985-w10.1038/s41467-020-17985-w ↗
19. 10.1080/15548627.2022.204734110.1080/15548627.2022.2047341 ↗
20. 10.1002/hep.2882010.1002/hep.28820 ↗
21. 10.1016/j.ymthe.2021.09.01610.1016/j.ymthe.2021.09.016 ↗
22. 10.1194/jlr.M09096910.1194/jlr.M090969 ↗
23. 10.1002/advs.20200227310.1002/advs.202002273 ↗
24. 10.1080/15548627.2020.171210710.1080/15548627.2020.1712107 ↗
25. 10.1507/endocrj.EJ20-032610.1507/endocrj.EJ20-0326 ↗
26. 10.1007/s40265-018-0983-610.1007/s40265-018-0983-6 ↗
27. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
28. 10.1039/D0BM01609H10.1039/D0BM01609H ↗
29. 10.1016/j.addr.2023.11499010.1016/j.addr.2023.114990 ↗
30. 10.1021/acs.nanolett.2c0323410.1021/acs.nanolett.2c03234 ↗
31. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
32. 10.1016/j.celrep.2018.02.01410.1016/j.celrep.2018.02.014 ↗
33. 10.1126/sciadv.abc945010.1126/sciadv.abc9450 ↗
34. 10.1056/NEJMoa181742610.1056/NEJMoa1817426 ↗
35. 10.1073/pnas.202040111810.1073/pnas.2020401118 ↗
36. 10.1016/j.jconrel.2023.09.04010.1016/j.jconrel.2023.09.040 ↗
37. 10.1016/S0140-6736(19)33041-710.1016/S0140-6736(19)33041-7 ↗
38. 10.1016/S0140-6736(15)00803-X10.1016/S0140-6736(15)00803-X ↗
39. 10.1016/j.jhep.2017.11.01410.1016/j.jhep.2017.11.014 ↗
40. 10.1016/j.plipres.2023.10123810.1016/j.plipres.2023.101238 ↗
41. 10.1016/j.diabet.2023.10143210.1016/j.diabet.2023.101432 ↗
42. 10.1002/hep.2176310.1002/hep.21763 ↗
43. 10.1038/srep4665810.1038/srep46658 ↗
44. 10.1016/j.cmet.2006.03.00710.1016/j.cmet.2006.03.007 ↗
45. 10.1073/pnas.140852311110.1073/pnas.1408523111 ↗
46. 10.1016/j.freeradbiomed.2023.08.03110.1016/j.freeradbiomed.2023.08.031 ↗
47. 10.1080/15548627.2023.225973210.1080/15548627.2023.2259732 ↗
48. 10.1080/15548627.2023.225419110.1080/15548627.2023.2254191 ↗
49. 10.1016/j.jhep.2013.01.01110.1016/j.jhep.2013.01.011 ↗
50. 10.3389/fendo.2020.60162710.3389/fendo.2020.601627 ↗
51. 10.1016/j.jhep.2022.04.01010.1016/j.jhep.2022.04.010 ↗
52. 10.1097/HEP.000000000000037510.1097/HEP.0000000000000375 ↗
53. 10.1186/s12951-021-01189-510.1186/s12951-021-01189-5 ↗
54. 10.1186/s12951-022-01689-y10.1186/s12951-022-01689-y ↗
55. 10.1002/adhm.20230147110.1002/adhm.202301471 ↗
56. 10.1136/gut.2010.22284410.1136/gut.2010.222844 ↗
57. 10.1038/s41467-021-27539-310.1038/s41467-021-27539-3 ↗
58. 10.1038/s41421-019-0091-010.1038/s41421-019-0091-0 ↗
59. Bailey‐Hytholt C. M. · J. Vis. Exp. · 2021 · 168
60. 10.2147/IJN.S36696210.2147/IJN.S366962 ↗
61. 10.1038/s41565-021-01032-w10.1038/s41565-021-01032-w ↗
62. 10.1080/15548627.2020.183471110.1080/15548627.2020.1834711 ↗
63. 10.1016/j.jconrel.2018.04.02210.1016/j.jconrel.2018.04.022 ↗
64. 10.3389/fonc.2022.84558310.3389/fonc.2022.845583 ↗
65. 10.1038/s41596-022-00710-w10.1038/s41596-022-00710-w ↗